CBHD Stock Overview Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Coloplast A/S Competitors Price History & Performance
Summary of share price highs, lows and changes for Coloplast Historical stock prices Current Share Price DKK 111.60 52 Week High DKK 130.45 52 Week Low DKK 103.70 Beta 0.35 1 Month Change 5.33% 3 Month Change -4.45% 1 Year Change 4.20% 3 Year Change -14.97% 5 Year Change -8.00% Change since IPO 1,330.77%
Recent News & Updates
Insufficient new directors Dec 30 An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B). Dec 05
Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy Nov 15
Final dividend of kr.17.00 announced Nov 08
Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025 Nov 06
Full year 2024 earnings released: EPS: kr.22.46 (vs kr.22.21 in FY 2023) Nov 05 See more updates
Insufficient new directors Dec 30 An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B). Dec 05
Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy Nov 15
Final dividend of kr.17.00 announced Nov 08
Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025 Nov 06
Full year 2024 earnings released: EPS: kr.22.46 (vs kr.22.21 in FY 2023) Nov 05 Coloplast A/S Recommends the Distribution of Year-End Dividend Coloplast A/S to Report First Half, 2025 Results on May 06, 2025
Coloplast A/S, Annual General Meeting, Dec 04, 2025 Sep 27
Third quarter 2024 earnings released: EPS: kr.5.67 (vs kr.5.99 in 3Q 2023) Aug 21
Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24 Aug 20
First half dividend of kr.5.00 announced May 09 Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24
New major risk - Financial position May 07
Second quarter 2024 earnings released: EPS: kr.5.57 (vs kr.5.44 in 2Q 2023) May 07
First quarter 2024 earnings released Feb 11 Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24
Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US Feb 01
Coloplast A/S Approves the Distribution of Year-End Dividend Dec 08 Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024
Now 21% undervalued after recent price drop Nov 10
Full year 2023 earnings released Nov 10 Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024
Deputy Chairman recently bought €5.4m worth of stock Sep 03
Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC Sep 02
New minor risk - Shareholder dilution Sep 01
Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC Sep 01
Third quarter 2023 earnings released: EPS: kr.5.99 (vs kr.6.07 in 3Q 2022) Aug 18
Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023 Aug 17
Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion. Jul 08
Coloplast A/S Provides Earnings Guidance for the Fiscal 2023 May 11
First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022) Feb 05
Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections Feb 04
Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23 Feb 03
Upcoming dividend of kr.15.00 per share Nov 25
Less than half of directors are independent Nov 16
Coloplast Announces Executive Changes Nov 16
Full year 2022 earnings released: EPS: kr.22.17 (vs kr.22.67 in FY 2021) Nov 09 Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023 Coloplast Launches Saffron™ Fixation System for Prolapse Repair Oct 07
Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023
Third quarter 2022 earnings released Aug 18
Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022 Aug 18
Coloplast A/S Provides Earnings Guidance for the Full Year of 2022 May 08
Second quarter 2022 earnings released May 06
Less than half of directors are independent Apr 27
Contraline Names Yelena Tropsha as CTO Apr 06
Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners. Feb 01
First quarter 2022 earnings: Revenues exceed analyst expectations Jan 26
Coloplast A/S Updates Earnings Guidance for the Year 2021/22 Jan 26
Independent Director Birgitte Nielsen has left the company Dec 03
Upcoming dividend of kr.14.00 per share Nov 27
Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020) Nov 07
Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020) Aug 22
Coloplast A/S Provides Earnings Guidance for the Year 2020/2021 Aug 20 Coloplast A/S Provides Earnings for the Year 2021
Second quarter 2021 earnings released May 07
New 90-day low: €117 Mar 06
First quarter 2021 earnings released Feb 03
Revenue beats expectations Feb 03
New 90-day high: €136 Feb 03
New 90-day low: €119 Jan 14
Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors Dec 04
Upcoming Dividend of kr.13.00 Per Share Nov 27
New 90-day low: €122 Nov 24
Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million. Nov 05
Revenue misses expectations Nov 05
New 90-day low: €128 Oct 27
New 90-day low: €130 Oct 06
New 90-day low - €132 Sep 09 Coloplast A/S to Report First Half, 2021 Results on May 06, 2021
Earnings released Aug 19
New 90-day low - €137 Aug 15 Shareholder Returns CBHD DE Medical Equipment DE Market 7D 2.3% 1.8% 2.0% 1Y 4.2% -3.5% 15.2%
See full shareholder returns
Return vs Market: CBHD underperformed the German Market which returned 14.1% over the past year.
Price Volatility Is CBHD's price volatile compared to industry and market? CBHD volatility CBHD Average Weekly Movement 3.1% Medical Equipment Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: CBHD has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: CBHD's weekly volatility (3%) has been stable over the past year.
About the Company Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.
Show more Coloplast A/S Fundamentals Summary How do Coloplast's earnings and revenue compare to its market cap? CBHD fundamental statistics Market cap €25.10b Earnings (TTM ) €677.17m Revenue (TTM ) €3.62b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CBHD income statement (TTM ) Revenue DKK 27.03b Cost of Revenue DKK 8.76b Gross Profit DKK 18.27b Other Expenses DKK 13.22b Earnings DKK 5.05b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 04, 2025
Earnings per share (EPS) 22.44 Gross Margin 67.59% Net Profit Margin 18.69% Debt/Equity Ratio 120.6%
How did CBHD perform over the long term?
See historical performance and comparison Dividends
2.6% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 22:47 End of Day Share Price 2025/01/30 00:00 Earnings 2024/09/30 Annual Earnings 2024/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Coloplast A/S is covered by 48 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null ABG Sundal Collier Robert Bate Barclays Hassan Al-Wakeel Barclays
Show 45 more analysts 
